Yinchen Shen
Overview
Explore the profile of Yinchen Shen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
478
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cheng L, Hu Q, Wang Y, Nie W, Lu H, Zhang B, et al.
Adv Sci (Weinh)
. 2024 Dec;
12(5):e2407652.
PMID: 39680684
N6-methyladenosine (mA) serves as one of the crucial RNA modifications for genes involved in cancer progression. Here, 7273 expression quantitative trait loci potentially regulating 30 m6A pathway genes are identified...
2.
Chang Q, Li J, Zhu Y, Qiang H, Lu H, Shen Y, et al.
J Thorac Dis
. 2024 Dec;
16(11):7546-7560.
PMID: 39678908
Background: For patients with early non-small cell lung cancer (NSCLC) complicated with chronic obstructive pulmonary disease (COPD), the efficacy and safety of immunotherapy are still unclear. This study was designed...
3.
Nie W, Zheng L, Shen Y, Zhang Y, Teng H, Zhong R, et al.
Chin Med J (Engl)
. 2024 Nov;
138(3):346-348.
PMID: 39602314
No abstract available.
4.
Liu H, Zhou C, Jiang H, Chu T, Zhong R, Zhang X, et al.
Front Immunol
. 2024 Nov;
15:1430301.
PMID: 39502692
Background: Chemotherapy combined with PD-1 inhibitor treatment has revolutionized the standard of care for patients with NSCLC. However, the benefit is not universal, highlighting the need for precise prediction factors....
5.
Zheng L, Hu F, Nie W, Lu J, Zhang B, Xu J, et al.
Cancer Med
. 2024 Sep;
13(17):e70223.
PMID: 39258530
Background: The 9th edition of the TNM Classification for lung cancer delineates M1c into two subcategories: M1c1 (Multiple extrathoracic lesions within a single organ system) and M1c2 (Multiple extrathoracic lesions...
6.
Li J, Lu H, Chu T, Hu F, Qian J, Shen Y
Chin Med J (Engl)
. 2024 Sep;
137(19):2384-2386.
PMID: 39245641
No abstract available.
7.
Wei J, Xu Y, Wang H, Niu T, Jiang Y, Shen Y, et al.
Comput Methods Programs Biomed
. 2024 Aug;
256:108382.
PMID: 39213898
Objective: In diabetes mellitus patients, hyperuricemia may lead to the development of diabetic complications, including macrovascular and microvascular dysfunction. However, the level of blood uric acid in diabetic patients is...
8.
Zheng L, Hu F, Huang L, Lu J, Yang X, Xu J, et al.
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38641349
Background: Combining immune checkpoint inhibitors (ICIs) with chemotherapy has become a standard treatment for patients with non-small cell lung cancer (NSCLC) lacking driver gene mutations. Reliable biomarkers are essential for...
9.
Li J, Xie M, Zhao R, Qiang H, Chang Q, Qian J, et al.
Front Oncol
. 2024 Apr;
14:1357231.
PMID: 38567147
Background: For patients with EGFR/HER2 exon20 insertions, platinum-containing double-drug chemotherapy is still the standard treatment method. First-generation TKIs have almost no therapeutic activity against EGFR exon 20 insertions. The efficacy...
10.
Wei J, Chen C, Shen Y, Li F, Yiyang S, Liu H
BMC Ophthalmol
. 2024 Feb;
24(1):76.
PMID: 38373920
Aims: To find potential relation between retrobulbar vessels and fundus microvessels and to detect sensitive and effective clinical indicators in predicting the progress of diabetic retinopathy (DR), ocular hemodynamics were...